The Patent Finder

Mereo Biopharma 5, Inc.

Also on record
Records under this name other than the patents Mereo Biopharma 5, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 46 patents it holds.

Back to Mereo Biopharma 5, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,136,384Methods for Treatment of Cancer Comprising Tigit-Binding Agents
In force
 · High confidence
In forceHigh confidence
US 11,230,596Methods for Treatment of Cancer Comprising Tigit-Binding Agents
In force
 · High confidence
In forceHigh confidence
US 8,324,361Nucleic Acid Molecules Encoding Soluble Frizzled (FZD) Receptors
Term ended
Term ended Oct 31, 2026 · High confidence
Term endedTerm ended Oct 31, 2026High confidence
US 9,228,013Methods of Using the Fri Domain of Human Frizzled Receptor for Inhibiting WNT Signaling in a Tumor or Tumor Cell
Term ended
Term ended Oct 31, 2026 · High confidence
Term endedTerm ended Oct 31, 2026High confidence
US 9,732,139Methods of Treating Cancer by Administering a Soluble Receptor Comprising a Human FC Domain and the Fri Domain from Human Frizzled Receptor
Term ended
Term ended Oct 31, 2026 · High confidence
Term endedTerm ended Oct 31, 2026High confidence
US 9,850,311Compositions and methods for diagnosing and treating cancer
Term ended
Term ended Oct 31, 2026 · High confidence
Term endedTerm ended Oct 31, 2026High confidence
US 8,784,811Method of Treating Cancer Using Antibodies to a Non-Ligand Binding Region of NOTCH1
Lapsed on the fee record
Ended Jul 22, 2026 · High confidence
Lapsed on the fee recordEnded Jul 22, 2026High confidence
US 8,765,913Human Frizzled (FZD) Receptor Polypeptides and Methods of Use Thereof for Treating Cancer and Inhibiting Growth of Tumor Cells
Lapsed on the fee record
Ended Jul 1, 2026 · High confidence
Lapsed on the fee recordEnded Jul 1, 2026High confidence
US 9,982,042Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent
Lapsed on the fee record
Ended May 29, 2026 · High confidence
Lapsed on the fee recordEnded May 29, 2026High confidence
US 8,551,479Methods for Treating Melanoma
Lapsed on the fee record
Ended Oct 8, 2025 · High confidence
Lapsed on the fee recordEnded Oct 8, 2025High confidence
10 of 15 records shown.
Pro members see all 15.
Pro members: see all 15 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited